Trial · NCT03913559
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
NCT03913559, Phase 2, Terminated, St. Jude Children's Research Hospital
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia. Trials, record NCT03913559. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT03913559
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
- NCT number
- NCT03913559
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 5 participants, actual
- Lead sponsor
- St. Jude Children's Research Hospital
- Conditions
- Acute Lymphoblastic Leukemia
- Interventions
- Inotuzumab ozogamicin, Methotrexate, Hydrocortisone, Cytarabine, Diphenhydramine, Acetaminophen, Methylprednisolone
- First posted
- 2019-04-12
- Last updated
- 2026-02-12
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Treatment response Cycle1 - count | At the end of cycle 1 (each cycle is 28 days) | Number of patients that reach MRD negative at the end of cycle 1 |
| Primary | Treatment Response Cycle 1 - percentage | At the end of cycle 1 (each cycle is 28 days) | Percentage of patients that reach MRD negative at the end of cycle 1 |
| Primary | Treatment Response Cycle 2 - count | At the end of cycle 2 (each cycle is 28 days) | Number of patients that reach MRD negative at the end of cycle 2 |
| Primary | Treatment Response Cycle 2 - percentage | At the end of cycle 2 (each cycle is 28 days) | Percentage of patients that reach MRD negative at the end of cycle 2 |
| Secondary | Occurrence of death - count | up to 30 days from last dose of inotuzumab ozogamicin or up to 30 days post-transplant among the patients who proceed to transplant | Number of patient deaths that occur at any time during observation on study |
| Secondary | Occurrence of death - percentage | up to 30 days from last dose of inotuzumab ozogamicin or up to 30 days post-transplant among the patients who proceed to transplant | Percentage of patient deaths that occur at any time during observation on study |
| Secondary | Occurrence of Veno-occlusive disease (VOD) - count | up to 30 days from last dose of inotuzumab ozogamicin or up to 30 days post-transplant among the patients who proceed to transplant | Number of patients that develop VOD at any time during observation on study |
| Secondary | Occurrence of Veno-occlusive disease (VOD) - percentage | up to 30 days from last dose of inotuzumab ozogamicin or up to 30 days post-transplant among the patients who proceed to transplant | Percentage of patients that develop VOD at any time during observation on study |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers2
The papers the trial lists on ClinicalTrials.gov.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT03913559
GET https://conductscience.org/api/trials/v1/NCT03913559/registered